Lupin spins out Kaveri Therapeutics, transferring rights to two cancer drug candidates, including PRMT5 inhibitor LNP7457, and acquires 82.2% stake.
Generic Giant's New Strategy: Spin-off for Innovative Drugs
Lupin Limited (NSE: LUPIN), a leading Indian generic pharmaceutical company, has established Kaveri Therapeutics, a US-based oncology-focused startup, to efficiently develop its high-risk, high-reward innovative drug pipeline. This spin-off allows Lupin to independently value its innovative drug assets and facilitate external capital raising. This strategic decision aims to mitigate the risks associated with developing innovative drugs while maintaining the stable cash flow of its existing generic business. Lupin secures an 82.2% stake in Kaveri in exchange for licensing its assets, maintaining its position as the majority shareholder.
Clinical Value of Transferred Oncology Pipeline
The assets exclusively licensed to Kaveri include two key compounds targeting metastatic solid tumors. The first, LNP7457, is a PRMT5 (Protein Arginine Methyltransferase 5) inhibitor, which presented positive Phase 1 clinical data at the 2025 American Society of Clinical Oncology (ASCO) meeting. The second, LNP8701, is a SOS1 (Son of Sevenless 1) inhibitor, targeting the RAS-MAPK signaling pathway, with initial first-in-human data reported earlier this year. Both candidates have demonstrated favorable safety profiles and preliminary efficacy in solid tumor patients, paving the way for future Phase 2 trials.
Alignment with Global Big Pharma Targets and Differentiation
The targets acquired by Kaveri are areas of active development by global pharmaceutical companies, increasing the potential for future partnerships. In the PRMT5 field, Bristol Myers Squibb (BMS) is conducting Phase 2/3 trials with navlimetostat, and AstraZeneca and Ideaya Biosciences are also actively involved. In the SOS1 inhibitor field, Bayer and Boehringer Ingelheim have entered the market, but BMS has discontinued its related assets and trials, creating a less competitive landscape. Therefore, if Kaveri can demonstrate unique safety and combination therapy data, it can create attractive opportunities for technology transfer as a later entrant.
Leveraging the US Biotech Ecosystem for Funding
Kaveri has established an independent management structure focused on the US market by appointing Kristi Jones as CEO and Robert Pierce, MD, as CMO. In addition to the initial capital from Lupin, Kaveri plans to pursue significant external funding through US venture capital. The market for metastatic solid tumor treatments is substantial, valued at $96.53 billion in 2025, but global clinical trials require significant investment. Kaveri aims to accelerate the progress of its Phase 2 and 3 trials by securing funding within the advanced US biotech ecosystem, such as in Boston or San Francisco.
The spin-out of Kaveri Therapeutics by Lupin Limited represents a significant long-term financial milestone, as it allows the generic company to independently value its high-risk oncology pipeline and secure efficient funding channels. The Phase 1-completed PRMT5 inhibitor LNP7457 and SOS1 inhibitor LNP8701 align with the target pipelines of global big pharma companies such as BMS, AstraZeneca, and Bayer, making them attractive assets for potential large-scale technology transfer or co-development partnerships. The metastatic solid tumor market is a massive $96.53 billion market in 2025, and Kaveri Therapeutics plans to accelerate subsequent clinical development by securing external venture capital funding in the US market. Investors should closely monitor Kaveri's subsequent capital raising performance and the acquisition of global clinical data, as this will impact the valuation of Lupin's 82.2% stake and the re-evaluation of its oncology drug development capabilities in the short term.
Source: FierceBiotech (rss)